pic_kunle_odunsiDr. Kunle Odunsi is the Chair of the Department of Gynaecologic Oncology at Roswell Park Cancer Institute (RPCI) and Professor of Obstetrics and Gynaecology at the University of Buffalo. He is also the Co-Leader of the Tumour Immunology and Immunotherapy Cancer Center Program and Executive Director of the Center for Immunotherapy at RPCI. Dr. Odunsi maintains an active research program focused on understanding the mechanisms of immune recognition and tolerance in ovarian cancer. He is the Principal Investigator of an NCI funded multi-million dollar Specialized Program of Research Excellence (SPORE) in ovarian cancer.

After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, Dr. Odunsi completed postgraduate training in Obstetrics and Gynaecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. He then completed a research fellowship in Molecular Oncology and earned his Ph.D. at the Imperial Cancer Research Fund Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, UK. Subsequently, he completed residency training in Obstetrics & Gynaecology at the Yale University School of Medicine and clinical fellowship in Gynaecologic Oncology at RPCI. He is a fellow of the Royal College of Obstetricians and Gynaecologists in the United Kingdom (since 1991) and the American College of Obstetricians and Gynaecologists. In 2014, he was elected Fellow of the Nigerian Academy of Science.

Dr. Odunsi has authored or co-authored more than 200 journal publications and book chapters. He has served on several Scientific Review Sections of the National Institutes of Health and as a reviewer for the French National Cancer Institute, Swiss Cancer League, Italian Association for Cancer Research, Hong Kong Cancer Institute and European Commission. Dr. Odunsi is the recipient of numerous awards and honours including the Anna-Marie Kellen Clinical Investigator Award; Achievement in Healthcare Award; and Thomas B. Tomasi Hope award for his significant advances in the fight against cancer and bringing hope to cancer patients.